Kiniksa Pharmaceuticals International, plc (KNSA) fundamentals score
Kiniksa Pharmaceuticals International is a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 7.2 out of 10, Good long-term fundamentals
- Growth: 6.1/10
- Profitability: 8.6/10
- Financial health: 9.8/10
- Earnings quality: 7.9/10
- Valuation: 2.8/10
Scores are calculated from Kiniksa Pharmaceuticals International, plc’s SEC filings, using the 12 months through 2026-03. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10